Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

840

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

Muscular Invasive Bladder Cancer (MIBC)

Interventions

DRUG

SHR-A2102；Adebrelimab

Treatment with SHR-A2102 in combination with fixed dose Adebrelimab

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY